Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Deffered Revenue (2021 - 2025)

Historic Non-Current Deffered Revenue for Viridian Therapeutics, Inc.\DE (VRDN) over the last 5 years, with Q2 2025 value amounting to $140000.0.

  • Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue fell 6728.97% to $140000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $140000.0, marking a year-over-year decrease of 6728.97%. This contributed to the annual value of $284000.0 for FY2024, which is 5043.63% down from last year.
  • Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue amounted to $140000.0 in Q2 2025, which was down 6728.97% from $212000.0 recorded in Q1 2025.
  • Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue's 5-year high stood at $1.1 million during Q4 2021, with a 5-year trough of $140000.0 in Q2 2025.
  • Its 5-year average for Non-Current Deffered Revenue is $644600.0, with a median of $645000.0 in 2023.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first crashed by 2506.53% in 2022, then plummeted by 6728.97% in 2025.
  • Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue (Quarter) stood at $1.1 million in 2021, then dropped by 25.07% to $861000.0 in 2022, then crashed by 33.45% to $573000.0 in 2023, then crashed by 50.44% to $284000.0 in 2024, then tumbled by 50.7% to $140000.0 in 2025.
  • Its Non-Current Deffered Revenue stands at $140000.0 for Q2 2025, versus $212000.0 for Q1 2025 and $284000.0 for Q4 2024.